The goal of this psychotherapy clinical trial is to evaluate whether a algorithm-based personalized modular psychotherapy is more effective than usual individual psychotherapy in treating major depressive disorder complicated by personality dysfunction and/or complex trauma in adults aged 18 to 65 receiving care in the Chilean public mental health system. The main questions it aims to answer are: * Does algorithm-based modular psychotherapy lead to greater clinically significant reduction and remission of depressive symptoms compared to usual psychotherapy? * Does algorithm-based modular psychotherapy lead to greater improvement in emotional regulation, interpersonal functioning, and self-related functioning, including changes observed in daily life? Researchers will compare algorithm-based modular psychotherapy to usual individual psychotherapy provided in public community mental health centers to see if the modular, personalized approach results in better clinical outcomes, stronger therapeutic alliance, and higher treatment satisfaction. Participants will: * Be randomly assigned to receive either algorithm-based modular psychotherapy or usual individual psychotherapy * Attend weekly individual psychotherapy sessions * Complete structured diagnostic interviews and self-report questionnaires before, during, and after treatment * Provide brief daily reports on mood, emotions, and interpersonal experiences using a smartphone before and after treatment
This randomized controlled clinical trial evaluates an algorithm-based personalized modular psychotherapy designed for adults with major depressive disorder whose condition is complicated by long-standing emotional, interpersonal, and self-related difficulties associated with early life adversity or personality functioning problems. These individuals often have poorer outcomes with standard psychotherapeutic approaches offered in public mental health services. The experimental intervention consists of a modular psychotherapy approach. All participants in this group receive a core, evidence-based depression treatment. Additional short therapy modules are added based on each participant's baseline clinical profile following a module-assignment algorithm, targeting specific difficulties such as problems with emotion regulation, sensitivity to rejection and interpersonal threat, difficulties in social functioning, or disturbances in self-concept and self-worth. The number and type of modules are personalized for each participant, allowing the treatment to be tailored while remaining feasible within routine public mental health care. The comparison group receives usual individual psychotherapy, which reflects standard care provided in community mental health centers in Chile. These treatments are delivered weekly by trained clinicians and are not guided by the modular protocol. 150 adults aged 18 to 65 will be recruited from public mental health centers. Eligible participants have major depressive disorder along with evidence of personality-related dysfunction and/or moderate to severe early life trauma. Participants are randomly assigned in a 1:1 ratio to either modular psychotherapy or usual care. The primary outcomes of the study are clinically meaningful reduction in depressive symptoms and remission from depression following treatment. Secondary outcomes include changes in emotional regulation, interpersonal functioning, daily emotional and interpersonal experiences assessed through brief smartphone-based daily reports, quality of the therapeutic alliance, and satisfaction with treatment from both patients and therapists. The purpose of this pilot trial is to determine whether a personalized algorithm-based modular psychotherapy approach improves clinical and functional outcomes compared to usual psychotherapy for people with complex depression in the Chilean public health system, and to inform future implementation and scaling of personalized mental health interventions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
The MIND intervention is an algorithm-based, personalized, modular psychotherapy for adults with depression complicated by personality dysfunction and/or complex trauma. All participants receive a core evidence-based depression treatment that includes behavioral activation, cognitive, and interpersonal psychotherapy strategies. Additional short therapy modules are selected based on each participant's baseline emotional, interpersonal, and self-related functioning profile, using a predefined clinical algorithm. These modules target specific difficulties such as emotion regulation problems (DBT Module), sensitivity to rejection and interpersonal threat (MBT and CBASP Modules), social functioning difficulties (Social Thinning Module). The type and number of modules are tailored to individual needs following an algorithm based on baseline measures (DERS, A-RSQ, OQ-45-IR). Treatment is delivered as weekly individual psychotherapy sessions.
Psychotherapy as usual (TAU) consists of individual psychotherapy delivered in public community mental health centers according to routine clinical practice. Treatment is provided weekly by trained clinicians and may vary in therapeutic orientation, techniques, and structure depending on the therapist and center. TAU is not guided by the modular psychotherapy protocol or algorithm used in the experimental intervention and reflects standard care available in the Chilean public mental health system.
CDT CASR
Santiago, Chile
COSAM La Bandera
Santiago, Chile
COSAM La Granja
Santiago, Chile
COSAM La Pintana
Santiago, Chile
COSAM Rinconada
Santiago, Chile
Depression remission.
Primary depression outcomes will be assessed using the MINI International Neuropsychiatric Interview. The MINI is a structured interview. Remission is defined as a negative MINI assessment for major depressive disorder.
Time frame: Baseline (pre-intervention), end of treatment (session 15; approximately 3 months), and 3-month post-treatment (approximately 6 months after baseline assessment).
Clinically significant symptom reduction
Clinically significant symptom reduction will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 has a range between 0 and 27. Higher scores indicate more symptom severity. Clinically significant symptom reduction is defined as a reduction of at least 5 points on the PHQ-9 from baseline and a post-treatment PHQ-9 score ≤9.
Time frame: Baseline (pre-intervention), end of treatment (session 15; approximately 3 months), and 3-month post-treatment (approximately 6 months after baseline assessment).
Emotional regulation difficulties
Emotional regulation will be assessed using the Difficulties in Emotion Regulation Scale (DERS-E). The DERS has a range of 25 to 125. Higher scores indicate more emotion regulation difficulties.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Interpersonal sensitivity and rejection sensitivity
Interpersonal sensitivity will be assessed using the Adult Rejection Sensitivity Questionnaire (A-RSQ). Changes in sensitivity to interpersonal rejection will be evaluated from baseline to post-treatment. The A-RSQ has a range of 1 to 36. Higher scores indicate more rejection sensitivity.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Interpersonal functioning and social problems
Interpersonal functioning will be measured using the Interpersonal Relations subscale of the Outcome Questionnaire - Interpersonal Relations (OQ-45-IR). Changes in social and interpersonal problems will be assessed from baseline to post-treatment. The range of the OQ-45 is 0 to 44. Higher scores indicate more interpersonal problems.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Daily emotional and interpersonal functioning
Daily emotional and interpersonal functioning will be assessed using smartphone-based ecological momentary assessment (EMA). Participants will report momentary negative affect, interpersonal experiences, rejection sensitivity, and self-related experiences multiple times per day during one week before treatment and one week after treatment.
Time frame: One week prior to treatment initiation and one week following treatment completion (after 15 sessions; approximately 3 months after baseline assessment).
Therapeutic alliance
Therapeutic alliance will be assessed using the Working Alliance Inventory (WAI), completed by participants after each therapy session. Change in alliance quality over the course of treatment will be examined.The range of the WAI is 12 to 84. Higher scores indicate a better working alliance perceived by the patient.
Time frame: After each treatment session, from session 1 through session 15 (approximately 3 months)
Treatment satisfaction
Treatment satisfaction will be assessed in patients using the Client Satisfaction Questionnaire-8 (CSQ-8). The range of the CSQ-8 is 8 to 32. Higher scores indicate more satisfaction with the treatment.
Time frame: End of treatment (after session 15; approximately 3 months after baseline)
Improvements in Quality of life
Quality of life will be assessed using the Recovering Quality of Life questionnaire (ReQoL). Changes in quality of life will be evaluated from baseline to post-treatment and follow-up. The range of the ReQoL is 0 to 40. Higher scores indicate better perceived quality of life.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Acceptability of the Intervention
Therapist perspectives on the intervention will be assessed using the Acceptability of Intervention Measure (AIM). The range of the AIM is 0 to 5. Higher scores indicate more acceptability of the intervention.
Time frame: End of treatment (after session 15; approximately 3 months after baseline)
Feasibility of Intervention
Therapist perspectives on the feasibility of the intervention will be asses using the Feasibility of Intervention Measure (FIM). The range of the FIM is 0 to 5. Higher scores indicate that the intervention is considered more feasible by the therapists.
Time frame: End of treatment (after session 15; approximately 3 months after baseline)
Intervention Appropriateness
Therapist perspectives on the appropriateness of the intervention will be measured using the Intervention Appropriateness Measure (IAM). The range of the IAM is 0 to 5. Higher scores indicate higher intervention appropriateness.
Time frame: End of treatment (after session 15; approximately 3 months after baseline)
Disability/Functional Impairment
Patient's degree of disability and functional impairment will be assessed through the WHO Disability Assessment Schedule (WHODAS). The range of the WHODAS is 12 to 60. Higher scored indicates higher disability.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Personality Functioning
Patient's personality functioning will be assess using the Levels of Personality Functioning Scale (LPFS-BF). The range of the LPFS is 12 to 48. Higher socres indicate more personality dysfunction.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
Psychological Distress
Patient's psychological distress will be assessed using the Clinical Outcomes in Routine Evaluation - Outcome Measure Short Version (CORE-10). The rage of the CORE-10 is 0,8 to 3,2. Higher scores indicate more psychological distress.
Time frame: Baseline (pre-intervention); during treatment at sessions 5, 10, and 15; and 3-month post-treatment follow-up (approximately 6 months after baseline).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.